Sanofi said a reorganization of the company’s research and development operation in Germany and France would result in 466 job cuts in the two countries.
Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter 2019 profit and forecast a sharp rise in 2020 revenue from the company’s new migraine drug Ajovy.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
